Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

2.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Proposed Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Earnings Outlook For ImmunoPrecise Antibodies ↗
 
Via Benzinga
News headline image
ImmunoPrecise Antibodies's Earnings Outlook ↗
 
Via Benzinga
News headline image
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery
Via ACCESSWIRE
News headline image
ImmunoPrecise's BioStrand® Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery ↗
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, has announced that its subsidiary, BioStrand®, has launched an advanced Retrieval Augmented... 
Via Benzinga
News headline image
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
EXCLUSIVE: Antibody-Discovery Platform Provider ImmunoPrecise's Subsidiary Highlights Approach to Biological Sequence Retrieval ↗
ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary BioStrand has published a preprint of its white paper titled "New Paradigm for Biological Sequence Retrieval Inspired by Natural 
Via Benzinga
News headline image
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Provides Update on Growth Strategy and Recent Share Price Movement
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data
Via ACCESSWIRE
News headline image
Overcoming The Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data ↗
Biotechnology research involves a vast amount of complex information that spans different dimensions, such as the functions of proteins, the 3D structures of molecules and the genetic information... 
Via Benzinga
News headline image
How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research
Via ACCESSWIRE
News headline image
How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research ↗
The introduction of artificial intelligence (AI) in healthcare has revolutionized the field, allowing for a more personalized approach to patient care. AI algorithms have the ability to process and... 
Via Benzinga
Topics Artificial Intelligence
News headline image
ImmunoPrecise Antibodies Announces CFO Transition
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Board Refreshment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Responds to 13D Filing
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Earnings Scheduled For July 7, 2023 ↗
Companies Reporting Before The Bell • ImmunoPrecise Antibodies (NASDAQ:IPA) is expected to report quarterly loss at $0.13 per share on revenue of $4.31 million. 
Via Benzinga
News headline image
Costco, AZZ And 3 Stocks To Watch Heading Into Friday ↗
With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Investor Sentiment Drops Following Economic Reports ↗
The CNN Money Fear and Greed index showed some a decline in overall sentiment among U.S. investors on Thursday. The Dow Jones dropped more than 300 points on Thursday as investors assessed the recent... 
Via Benzinga
News headline image
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
“Convergence of AI and Biology: Companies at the Forefront of Transformative Innovations”:- IPA, MRKR, PRAX , RMED
Via AB Newswire
Topics Artificial Intelligence
News headline image
IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
From ImmunoPrecise Antibodies
Via Business Wire
Healthcare and AI “Paradigm Shift” Stocks in Focus: IPA, MGRX, INBS, RMED
Via AB Newswire
Topics Artificial Intelligence
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) Is Strategically Built To Advance The Future
Via AB Newswire
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.